Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
HRAS Q61L PLX7904 skin squamous cell carcinoma no benefit detail...
MAP2K1 E203K PIK3CA amp Metformin + Trametinib skin squamous cell carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02324608 Phase I Cetuximab Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer Completed USA 0
NCT02449681 Phase II TH-4000 Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS Terminated USA | AUS 0
NCT02721732 Phase II Pembrolizumab Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Active, not recruiting USA 0
NCT02760498 Phase II Cemiplimab Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma Completed USA | ITA | FRA | ESP | DEU | AUS 2
NCT02964559 Phase II Pembrolizumab Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer Active, not recruiting USA 0
NCT02978625 Phase II Nivolumab + Talimogene laherparepvec Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Active, not recruiting USA 0
NCT03108131 Phase II Atezolizumab + Cobimetinib Cobimetinib and Atezolizumab in Advanced Rare Tumors Completed USA 0
NCT03212404 Phase I Cosibelimab Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers Recruiting NZL | FRA | ESP | AUS 5
NCT03284424 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Adults With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) (MK-3475-629/KEYNOTE-629) Completed USA | GBR | FRA | ESP | DEU | CAN | AUS 3
NCT03524326 Phase I Cetuximab + Lenvatinib Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma Completed USA 0
NCT03539198 Phase 0 Nivolumab Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer Terminated USA 0
NCT03666325 Phase II Pembrolizumab Cetuximab + Pembrolizumab Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance (I-Tackle) Unknown status ITA 0
NCT03767348 Phase Ib/II Nivolumab + RP1 RP1 Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) Recruiting USA | GBR | FRA | ESP | DEU 0
NCT03816332 Phase I Ipilimumab + Nivolumab + Prednisone + Tacrolimus Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers Active, not recruiting USA 0
NCT03833167 Phase III Pembrolizumab Pembrolizumab Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630) Active, not recruiting USA | NZL | ITA | GBR | FRA | ESP | DEU | CAN | AUS 15
NCT03871348 Phase I SAR441000 Cemiplimab + SAR441000 A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors Terminated USA | NLD | FRA | ESP | DEU | BEL 0
NCT03889912 Phase I Cemiplimab Pre-Operative Cemiplimab Administered Intralesionally for Patients With Recurrent Cutaneous Squamous Cell Carcinoma Recruiting USA 0
NCT03894618 Phase I SL-279252 SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas Active, not recruiting USA | ESP | CAN | BEL 0
NCT03901573 Phase Ib/II Atezolizumab + NT-I7 High-Risk Skin Cancers With Atezolizumab Plus NT-I7 Terminated USA 0
NCT03936959 Phase I LY3434172 A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer Completed USA | FRA | BEL | AUS 1
NCT03944941 Phase II Avelumab Avelumab + Cetuximab Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer Active, not recruiting USA 0
NCT03969004 Phase III Cemiplimab Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma Recruiting USA | NZL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 6
NCT04050436 Phase II Cemiplimab + RP1 RP1 Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer (CERPASS) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | AUS 3
NCT04105543 Phase I CLR 131 CLR 131 Combined With Radiation for Head and Neck Cancer Active, not recruiting USA 0
NCT04154943 Phase II Cemiplimab Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma Active, not recruiting USA | DEU | AUS 0
NCT04160065 Phase I IFx-Hu2.0 Immunotherapy With IFx-Hu2.0 Vaccine for Advanced MCC or cSCC Active, not recruiting USA 0
NCT04163952 Phase I Panitumumab + Talimogene laherparepvec Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin Completed USA 0
NCT04204837 Phase II Nivolumab + Relatlimab Nivolumab Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin Recruiting AUT 0
NCT04260802 Phase Ib/II OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers Recruiting CAN 0
NCT04293679 Phase Ib/II Cotsiranib Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC Completed USA 0
NCT04301011 Phase Ib/II TBio-6517 Pembrolizumab + TBio-6517 Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (RAPTOR) Terminated USA | CAN 1
NCT04305795 Phase Ib/II ASP-1929 + Pembrolizumab ASP-1929 + Cemiplimab An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors Active, not recruiting USA 0
NCT04315701 Phase II Cemiplimab A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer Recruiting USA 0
NCT04339062 Phase I Cemiplimab Cemiplimab + Everolimus + Prednisone Cemiplimab + Prednisone + Sirolimus Cemiplimab in AlloSCT/SOT Recipients With CSCC (CONTRAC) Active, not recruiting USA 0
NCT04389632 Phase I SGN-B6A A Study of SGN-B6A in Advanced Solid Tumors Recruiting USA | GBR | FRA | ESP 1
NCT04423029 Phase Ib/II DF6002 DF6002 + Nivolumab A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA | FRA | ESP | AUS 0
NCT04428671 Phase I Cemiplimab Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer Recruiting USA 0
NCT04450901 Phase I YBL-006 Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors Active, not recruiting AUS 2
NCT04502888 Phase I SL-172154 Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin Terminated USA 0
NCT04521413 Phase Ib/II CFI-402411 + Pembrolizumab CFI-402411 Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies Recruiting USA | CAN 1
NCT04521621 Phase Ib/II Coxsackievirus A21 + Pembrolizumab A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) Terminated USA | ITA | FRA | ESP | DEU | CAN 8
NCT04620200 Phase II Ipilimumab + Nivolumab Nivolumab Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery (MATISSE) Recruiting NLD 0
NCT04632433 Phase II Cemiplimab Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell Carcinoma Active, not recruiting ITA 0
NCT04710498 Phase II Atezolizumab Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma Active, not recruiting USA 0
NCT04717375 Phase Ib/II BND-22 Study of BND-22 in Participants With Advanced Solid Tumors Recruiting USA 1
NCT04787042 Phase Ib/II Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067 Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 Recruiting USA 0
NCT04807777 Phase II Ruxolitinib Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma Active, not recruiting USA 0
NCT04808999 Phase II Pembrolizumab Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC) Active, not recruiting USA 0
NCT04819373 Phase II BDB001 BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors Completed USA 0
NCT04913220 Phase Ib/II Cemiplimab + THOR-707 A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers Active, not recruiting USA | ITA | FRA | ESP | DEU | AUS 1
NCT04916002 Phase II Cemiplimab + Vidutolimod CMP-001 in Combination With IV PD-1-Blocking Antibody in Subjects With Certain Types of Advanced or Metastatic Cancer Suspended USA | AUS 0
NCT04925713 Phase I IFx-Hu2.0 IFx-Hu2.0 for the Treatment of Patients With Skin Cancer Completed USA 0
NCT04975152 Phase I Cemiplimab Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma Recruiting USA 0
NCT04985825 Phase II Imgatuzumab Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma (I-PACE) Withdrawn 0
NCT05025813 Phase II Pembrolizumab Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma (DESQUAMATE) Recruiting AUS 0
NCT05043714 Phase I NG-641 + Nivolumab Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours (NEBULA) Recruiting USA | GBR 0
NCT05069935 Phase I Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors Terminated USA 0
NCT05070403 Phase II Afatinib Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma Recruiting USA 0
NCT05076760 Phase I MEM-288 Study of MEM-288 Oncolytic Virus in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC) Recruiting USA 0
NCT05085496 Phase I Atezolizumab Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous Squamous Cell Carcinoma Recruiting USA 0
NCT05086692 Phase Ib/II MDNA11 + Pembrolizumab A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) Recruiting USA | CAN | AUS 1
NCT05098405 Phase I MP0317 First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors Terminated NLD | FRA 0
NCT05220748 Phase I Pembrolizumab + RM-1995 RM-1995 RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC Withdrawn 0
NCT05256381 Phase II Pembrolizumab + SOT101 A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors Active, not recruiting USA | ITA | FRA | ESP | BEL 4
NCT05269381 Phase I Cyclophosphamide + Neoantigen peptide vaccine + Pembrolizumab + Sargramostim Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA) Recruiting USA 0
NCT05329792 Phase II Daromun L19IL2/L19TNF in Skin Cancer Patients Recruiting ITA | FRA | ESP 0
NCT05565417 Phase Ib/II IMT-009 Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas Recruiting USA 0
NCT05574101 Phase II Cemiplimab A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer Recruiting USA 0
NCT05620134 Phase Ib/II JK08 A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer Recruiting ESP | BEL 0
NCT05714553 Phase Ib/II Docetaxel + Leucovorin + NUC-3373 Leucovorin + NUC-3373 + Pembrolizumab NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Recruiting GBR 0
NCT05729139 Phase I Cemiplimab + Peg-interferon alfa-2a Cemiplimab/Peg-Interferon-a in Advanced CSCC Withdrawn USA 0
NCT05821777 Phase Ib/II LB101 A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors Recruiting USA | FRA 0
NCT05858229 Phase Ib/II RP1 Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1. Recruiting USA 0
NCT05859074 Phase I MQ710 + Pembrolizumab MQ710 A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer Recruiting USA 0
NCT05878288 Phase II Cemiplimab Deep sequencIng in Cutaneous Squamous CEll caRciNomas (DISCERN) Recruiting AUS 0
NCT05888844 Phase II INCB099280 A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma Recruiting USA | NZL | NLD | FRA | ESP | CAN | AUS 13
NCT05896839 Phase Ib/II Ipilimumab + Nivolumab + Prednisone + Sirolimus Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer Recruiting USA 0
NCT05904496 Phase I BGB-30813 BGB-30813 + Tislelizumab A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-30813 Recruiting USA | ESP | AUS 0
NCT05938296 Phase I oHSV2-PD-L1/CD3-BsAb oHSV2-PD-L1/CD3-BsAb Administered Via Intramural Injection Recruiting USA 0
NCT06014086 Phase I PH-762 Intratumoral PH-762 for Cutaneous Carcinoma Recruiting USA 0
NCT06036836 Phase II Lenvatinib + Pembrolizumab Lenvatinib + MK-4280A MK-4280A Pembrolizumab Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Recruiting USA | NLD | CAN | AUS 3
NCT06090266 Phase Ib/II Cemiplimab + OR502 A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents Recruiting USA 0
NCT06295809 Phase II Pembrolizumab mRNA-4157 + Pembrolizumab A Study of (Neo)Adjuvant V940 and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007) Recruiting AUS 1
NCT06331598 Phase II Atezolizumab Atezolizumab + Tiragolumab A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) (IMperator) Recruiting ESP 0